

COMPLETE IF KNOWN

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature	/Magdalene Sgagias/	Date Considered	05/30/2010
-----------------------	---------------------	--------------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. M.S./

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

IAPG Rec'd PAT/STO 11 AUG 2006
 Approved for use through 7/31/2006. OMB 0651-0031
 SUBSTITUTE for PTO/SB/08A (07-05), Information Disclosure Statement by Applicant
 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
 1632

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

COMPLETE IF KNOWN**Application Number**

10/589180

Filing Date

August 18, 2006

First Named Inventor

La Monica, et al.

Group Art Unit

Examiner Name

Sheet

2

of

2

Attorney Docket Number

ITR0073YP

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

/Magdalene Sgagias/

Date
Considered

05/30/2010

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.S./

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

Receipt date: 08/11/2006

11 AUG 2006
 Approved for use through 7/31/2006. OMB 0651-0031
 SUBSTITUTE for PTO/SB/08A (07-05), Information Disclosure Statement by Applicant
 Patent and Trademark Office, US DEPARTMENT OF COMMERCE
 1632

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			COMPLETE IF KNOWN		
			Application Number	10/589180	
			Filing Date	August 11, 2006	
			First Named Inventor	La Monica, et al.	
			Group Art Unit		
			Examiner Name		
Sheet	3	of	4	Attorney Docket Number	ITR0073YP

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
M.S./		Beauchemin, et al., "Isolation and Characterization of Full-Length Functional cDNA Clones for Human Carcinoembryonic Antigen", Mol. and Cell. Biol., Vol. 7, No. 9, pp. 3221-3230, Sept. 1987.
		Benchimol, et al., "Carcinoembryonic Antigen, a Human Tumor Marker, Functions as an Intercellular Adhesion Molecule", Cell, Vol. 57, pp. 327-334, April 21, 1989.
		Berinstein, et al., "Carcinoembryonic Antigen as a Target for Therapeutic Anticancer Vaccines: a Review", J. of Clinical Oncology, Vol. 20, No. 8, pp. 2197-2207, April 15, 2002.
		Chen, et al., "Enhancement of DNA Vaccine Potency by Linkage of Antigen Gene to an HSP70 Gene", Cancer Research, Vol. 60, pp. 1035-1042, February 15, 2000.
		Cheng, et al., "Enhancement of Sindbis Virus Self-Replicating RNA Vaccine Potency by Linkage of Mycobacterium tuberculosis Heat Shock Protein 70 Gene to an Antigen Gene", J. of Immunol., Vol. 166, pp. 6218-6226, 2001.
		Chester, et al., "Recombinant anti-carcinoembryonic antigen antibodies for targeting cancer", Cancer Chemother. Pharmacol., Vol. 46 (Suppl) S2-S12, 2000.
		Gold, et al., "Demonstration of Tumor-Specific Antigens in Human Colonic Carcinomata by Immunological Tolerance and Absorption Techniques", J. Exp. Med., Vol. 121, pp. 439-462 (1965).
		Hammarstrom, et al., "Is There a Role for CEA in Innate Immunity in the Colon", Trends in Microbiology, Vol. 9, No. 3, pp. 119-125, 2001.
		Kantor, et al., "Immunogenicity and Safety of a Recombinant Vaccinia Virus Vaccine Expressing the Carcinoembryonic Antigen Gene in a Nonhuman Primate", Cancer Research, Vol. 52, pp. 6917-6925, 1992.
		King, et al., "DNA Vaccines With Single-Chain Fv Fused To Fragment C Of Tetanus Toxin Induce Protective Immunity Against Lymphoma and Myeloma", Nature Medicine, Vol. 4, No. 11, pp. 1281-1286, November 1998.
		Lathe, "Synthetic Oligonucleotide Probes Deduced from Amino Acid Sequence Data", J. Mol. Biol., Vol. 183, pp. 1-12, 1985.
		Liu, et al., "Recombinant Adeno-Associated Virus Expressing Human Papillomavirus Type 16 E7 Peptide DNA Fused with Heat Shock Protein DNA as a Potential Vaccine for Cervical Cancer", J. of Virol., Vol. 74, No. 6, pp. 2888-2894, March 2000.
		Lund, et al., "Signal sequence deletion and fusion to tetanus toxoid epitope augment antitumor immune responses to a human carcinoembryonic antigen (CEA) plasmid DNA vaccine in a murine test system", Cancer Gene Therapy, Vol. 10, pp. 365-376, 2003.
		Montgomery, et al., "Heterologous and Homologous Protection Against Influenza A by DNA Vaccination: Optimization of DNA Vectors", DNA and Cell Biology, Vol. 12, No. 9, pp. 777-783, 1993.
		Padua, et al., "PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia", Nature Medicine, Vol. 9, No. 11, pp. 1413-1417, November 2003.

Examiner Signature	/Magdalene Sgagias/	Date Considered	05/30/2010
--------------------	---------------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.S./
 SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

Receipt-date: 08/11/2006

IAP6 Rec'd PCT/PTO 11 AUG 2006

Approved for use through 7/31/2006. OMB 0651-0031
SUBSTITUTE for PTO/SB/08A (07-05), Information Disclosure Statement by Applicant
Patent and Trademark Office, US DEPT OF COMMERCE

1632

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			COMPLETE IF KNOWN		
			Application Number	10/589180	
			Filing Date	August 11, 2006	
			First Named Inventor	La Monica, et al.	
			Group Art Unit		
			Examiner Name		
Sheet	4	of	4	Attorney Docket Number	ITR0073YP

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
/M.S./		Paxton, et al., "Sequence Analysis of Carcinoembryonic Antigen: Identification of Glycosylation Sites and Homology With the Immunoglobulin Supergene Family", Proc. Natl. Acad. Sci. USA, Vol. 84, pp. 920-924, February 1987.
		Renard, et al., "HER-2 DNA and Protein Vaccines Containing Potent Th Cell Epitopes Induce Distinct Protective and Therapeutic Antitumor Responses in HER-2 Transgenic Mice", J. of Immunol., Vol. 171, pp. 1588-1595, 2003.
		Savalyeva, et al., "Plant viral genes in DNA idiotype vaccines activate linked CD4+ T-cell mediated immunity against B-cell malignancies", Nature Biotechnology, Vol. 19, pp. 760-764, August 2001.
		Scholl, et al., "Gene Therapy Applications to Cancer Treatment", J. of Biomed. and Biotech., Vol. 1, pp. 35-47, 2003.
		Screaton, et al., "Carcinoembryonic Antigen, A Human Tumor Marker, Cooperates with Myc and Bcl-2 in Cellular Transformation", J. of Cell Biology, Vol. 137, No. 4, pp. 939-952, May 19, 1997.
		Shiver, et al., "Cytotoxic T Lymphocyte and Helper T Cell Responses following HIV Polynucleotide Vaccination", Annals. New York Academy of Sciences, Vol. 772, pp. 198-208, 1995.
		Su, et al., "Enhanced Induction of Telomerase-specific CD4+ T Cells Using Dendritic Cells Transfected with RNA Encoding a Chimeric Gene Product", Cancer Research, Vol. 62, pp. 5041-5048, September 1, 2002.
		Thompson, et al., "Molecular cloning of a gene belonging to the carcinoembryonic antigen gene family and discussion of a domain model", Proc. Natl. Acad. Sci. USA, Vol. 84, pp. 2965-2969, May 1987.

Examiner Signature	/Magdalene Sgagias/	Date Considered	05/30/2010
--------------------	---------------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.S./
 SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005